Abstract: Sildenafi l is a selective inhibitor of phosphodiesterase type 5 (PDE-5). Its chronic administration has been shown to improve exercise capacity, World Health Organization functional class, and haemodynamics in patients with symptomatic pulmonary arterial hypertension (PAH). There is however, no data describing the clinical consequences of sudden cessation of sildenafi l treatment. In this series, 9 patients with NYHA Class II-IV PAH who were stable on 2 months of sildenafi l monotherapy, had their sildenafi l ceased to accommodate a 2-week washout period, required for enrollment in research involving an endothelin receptor antagonist. Six minute walk distance (SMWD) and clinical assessments were performed before cessation of sildenafi l, and again 2 weeks later. Over the course of this 2-week washout period, 6 of the 9 patients reported increased breathlessness and fatigue, 1 of these was hospitalized with worsening right heart failure. The SMWD fell in 6 patients, with falls of greater than 100 m recorded in 4 patients. This was accompanied by a worsening of NYHA Class from 2.5 ± 0.2 to 3.1 ± 0.1 (mean ± SEM, p = 0.01). These data indicate that sudden cessation of sildenafi l monotherapy, in patients with PAH, carries with it a signifi cant and unpredictable risk of rapid clinical deterioration. We recommend that if sildenafi l needs to be ceased, it would be more prudent to consider concurrent vasodilator therapy before the gradual cessation of sildenafi l.
Introduction
Sildenafi l is a selective inhibitor of phosphodiesterase type 5 . This is the predominant phosphodiesterase isoform in the lungs (Rabe et al 1994) . Sildenafi l inhibits the breakdown of cGMP, and enhances the ability of endothelial nitric oxide to vasodilate the pulmonary arteries, reducing intravascular calcium, relaxing smooth muscle cells and reducing pulmonary vascular resistance (PVR) (Corbin et al 1999) .
Acutely administered sildenafi l assists weaning from nitric oxide (Atz and Wessel 1999) , prolongs the effect of inhaled iloprost (Wilkens et al 2001; Ghofrani et al 2002) , reduces mean pulmonary artery pressure (MPAP) and PVR in the post heart transplant setting (Kulkarni et al 2004; Jabbour et al 2007) , enhances the reduction in PVR when used concomitantly with iNO (Michelakis et al 2002; Lepore et al 2002) and modifi es pulmonary arterial hypertension (PAH) secondary to acute hypoxia in normal volunteers (Zhao et al 2001) . Chronic administration of sildenafi l has been shown to improve exercise capacity, WHO functional class, and haemodynamics in patients with symptomatic PAH (Galie et al 2005) . Similarly, hemodynamic and functional benefi t has been demonstrated in a small group of patients with PAH secondary to chronic thromboembolic disease (Sheth et al 2005) . It is now established as a treatment for pulmonary hypertension in these patients. Though extensive data exist regarding the safety and effi cacy of sildenafi l therapy in PAH, there are no data describing the clinical consequences of sudden cessation of sildenafi l treatment.
Methods
In this series, 9 patients with NYHA Class II-IV PAH who were stable after 2 months of sildenafi l monotherapy 50mg, 4 times daily were followed. This dose was chosen prior to the publication of research that demonstrated the effi cacy of sildenafi l 20 mg, 3 times daily in the treatment of PAH (Galie et al 2005) . The average age of patients was 42 ± 13 years and the male to female ratio 5:4. Five patients were NYHA Class II, 3 patients were NYHA Class III, and 1 patient was NYHA Class IV. Six patients had idiopathic PAH (iPAH) and 3 had chronic thromboembolic pulmonary hypertension (CTEPH).
Around this time a separate clinical trial of bosentan, an endothelin receptor antagonist was to commence. This trial required a 2-week washout period of previous PAH-specifi c therapy including sildenafi l. Nine patients wished to participate in the bosentan study and had their sildenafi l therapy ceased. In order to investigate the consequences of sildenafi l cessation, six minute walk distance (SMWD) and clinical assessments were performed before cessation of sildenafi l, and again 2 weeks after cessation, before commencing bosentan. The study was approved by the St Vincent's Hospital Human Research Ethics Committee and no external fi nancial support was received. Informed consent was given by all subjects. Importantly, there were no access arrangements for ongoing sildenafi l use for PAH, either as monotherapy or combination therapy in Australia at the time of study.
Results
Over the course of this 2-week washout period 6 of the 9 patients reported increased breathlessness and fatigue, one was hospitalized with worsening right heart failure. The SMWD fell in 6 patients (3 with CTEPH and 3 with iPAH), with falls of greater than 100 m recorded in 4 patients (Figure 1 ). This was accompanied by a worsening of NYHA Class from 2.5 ± 0.2 to 3.1 ± 0.1 (mean ± SEM, p = 0.01). Deterioration was unrelated to the initial NYHA Class on sildenafi l. Fortunately, the condition of 4 of the 6 patients was stabilised with commencement of bosentan therapy. Two of the patients with CTEPH however, continued to deteriorate, one resumed sildenafi l and her condition restabilized, the other went on to have a successful pulmonary thromboendarterectomy (PTE) 2 months later. Three patients reported no change in their symptoms which correlated with stable SMWD.
Discussion
These data indicate that sudden cessation of sildenafi l monotherapy in patients with PAH carries with it a signifi cant and unpredictable risk of rapid clinical deterioration. "Rebound" pulmonary hypertension, which has been reported after withdrawal from calcium-antagonists (Rich and McLaughlin 1999) and prostacyclin (Channick et al 2001) refers to a worsening of PAH over and above what would be expected simply Sildenafi l cessation in PAH from the cessation of active treatment. To date, no such reports exist regarding sildenafi l. The theory that sildenafi l cessation may cause rebound PAH warrants further investigation with close hemodynamic monitoring, given the dramatic deterioration of the majority of patients in our series. The ongoing deterioration of the 2 patients with CTEPH highlights another issue. Recent data presented at the European Society of Cardiology 2007 Congress by Lang and colleauges (BENEFiT Study subgroup analysis) demonstrated that bosentan improved hemodynamics but had no signifi cant effect on exercise capacity (6MWD) in patients with inoperable CTEPH and those with post-pulmonary endarterectomy PAH. Research into the effectiveness of bosentan in treating the broader group of patients with CTEPH is ongoing. In our series, the restabilization of the two patients with CTEPH, after PTE and sildenafi l therapy respectively, is consistent with current evidence-based management (Klepetko et al 2004; Sheth et al 2005) . It is important to note that this series observed patients over a period of unavoidable cessation of sildenafi l monotherapy to gather valuable clinical information and was not designed to assess the effectiveness of bosentan therapy in rescuing patients off pulmonary vasodilator therapy.
In conclusion, we recommend that if sildenafi l needs to be ceased, that clinicians and patients should be aware of the potential risk of deterioration and patients should be closely monitored during this period. It may be more prudent to consider concurrent vasodilator therapy before the gradual cessation of sildenafi l.
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